Pharmacological Profiles of a Novel Aldose Reductase Inhibitor, SPR-210, and Its Effects on Streptozotocin-Induced Diabetic Rats.

スポンサーリンク

概要

• 論文の詳細を見る

• SPR-210 {2-[4-(4, 5, 7-trifluorobenzothiazol-2-yl)methyl-3-oxo-3, 4-dihydro-2<I>H</I>-1, 4-benzo-thiazin-2-yl] acetic acid}, a novel aldose reductase (AR) inhibitor, exhibited highly potent inhibition of partially purified AR from porcine lens (IC<SUB>50</SUB>=9.5×10<SUP>-9</SUP> M) and human placenta (IC<SUB>50</SUB>=1.0×10<SUP>-8</SUP>M). On the other hand, very weak inhibition by SPR-210 was observed against human placenta aldehyde reductase, which is the most closely related enzyme to AR, and against several adeninenucleotide-requiring enzymes. SPR-210 showed a noncompetitive mechanism with respect to DL-glyceraldehyde against porcine lens AR. Sorbitol accumulation in isolated human erythrocytes was effectively inhibited by SPR-210 during incubation with 50 mM glucose (IC<SUB>50</SUB>=1.6×10<SUP>-8</SUP>M). Oral administration of SPR-210 (1-30 mg/kg/day for 5 days) to streptozotocin-induced diabetic rats decreased the sorbitol contents in the sciatic nerve and lens (ED<SUB>50</SUB>=1.9 and 6.8 mg/kg/day, respectively). SPR-210 had higher potency in the lens than other AR inhibitors. Moreover, the deterioration in motor nerve conduction velocity in diabetic rats was ameliorated by treatment with SPR-210 (1-30mg/kg/day) accompanying the reduction in sorbitol content in the sciatic nerve. SPR-210 induced the recovery of the delayed peak latency of oscillatory potentials (O<SUB>1</SUB> O<SUB>4</SUB>) in the electroretinogram in diabetic rats (10 mg/kg/day). These results suggest that the specific AR inhibitor SPR-210 will be a useful therapeutic agent for preventing and improving some diabetic complications, especially diabetic neuropathy and retinopathy, and therefore, can be discriminated from other AR inhibitors.

• 公益社団法人 日本薬理学会の論文

著者

• NAKAMURA Yoshiyuki

  Pharmaceutical Research Laboratories, Sapporo Breweries Ltd.

• Kobayashi Fujio

  Pharmaceutical Research Laboratories Sapporo Breweries Ltd.

• Matsuura Akihiro

  Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma

• Matsui Tetsuo

  Pharmacology Department, Pharmaceutical Research Laboratories, Sapporo Breweries, Ltd.

• Matsuura Akihiro

  Pharmacology Department, Pharmaceutical Research Laboratories, Sapporo Breweries, Ltd.

• Nakamura Yoshiyuki

  Pharmacology Department, Pharmaceutical Research Laboratories, Sapporo Breweries, Ltd.

• Ishikawa Hiromichi

  Pharmacology Department, Pharmaceutical Research Laboratories, Sapporo Breweries, Ltd.

• Kobayashi Fujio

  Pharmacology Department, Pharmaceutical Research Laboratories, Sapporo Breweries, Ltd.

関連論文

• Therapeutic Potential of a Specific Chymase Inhibitor in Atopic Dermatitis
• Macrocarpals, Antibacterial Compounds from Eucalyptus, Inhibit Aldose Reductase
• Aspergillomarasmine A and B, Potent Microbial Inhibitors of Endothelin-converting Enzyme
• Amphotericin B Resistance Assay for the Detection of Cholesterol Biosynthesis Inhibitors
• Effects of a Novel Potent Aldose Reductase Inhibitor, GP : 1447, on Aldose Reductase Activity In Vitro and on Diabetic Neuropathy and Cataract Formation in Rats
• Pharmacological Profiles of Aspergillomarasmines as Endothelin Converting Enzyme Inhibitors.
• Pharmacological Profiles of a Novel Aldose Reductase Inhibitor, SPR-210, and Its Effects on Streptozotocin-Induced Diabetic Rats.

スポンサーリンク